Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc. The company headquarter is located in United States. The company was established in the 2022.

TickerCTOR
Long NameCitius Oncology Inc. Common Stock
Short NameCitius Oncology